Our findings observed that high-concentration PGD2 enhanced the anti-tumor activity of adriamycin and bendamustine in DLBCL (Fig. 4E), indicating the potential role of high-concentration PGD2 in combination chemotherapy for DLBCL treatment. This evidence concerns the gene HPGDS and diffuse large B-cell lymphoma.